HEALTH

ICN Insiders Move to Sell 56,915 Shares: Several officers and directors of ICN Pharmaceuticals Inc. have filed notices that they intend to sell thousands of shares of the drug maker’s stock, which is trading at near-record prices amid controversy over insider trading allegations against its chairman. Two officers and two directors notified regulators that they intend to sell the shares. The filings come as the Costa Mesa-based company faces a Securities and Exchange Commission probe, questions from a federal grand jury and shareholder lawsuits over Chairman Milan Panic’s sale of $1.2 million worth of ICN stock in 1994 before the company released negative news that triggered a 23% drop in price. But the new SEC notices don’t necessarily mean insiders expect more bad news to depress prices, which have been rising in recent months. ICN’s common stock climbed from $17.125 at the beginning of the year to a record $28 per share on May 22. It dropped 25 cents to $25.375 on Thursday on the New York Stock Exchange..